Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.66 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.62 |
| ▸ | APP | P05067 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 4/20 | 0.58 |
| ▸ | MAOA | P21397 | 3/20 | 0.58 |
| ▸ | SNCA | P37840 | 2/20 | 0.57 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | AR | P10275 | 1/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19183470 | 1.00 | AURKA (0.66) | AURKAABCG2APPMAOBMAOA | |
| SCHEMBL4450336 | 0.91 | ABCG2 (0.69) | AURKAABCG2APPSNCANFE2L2 | |
| SCHEMBL4450332 | 0.91 | ABCG2 (0.69) | AURKAABCG2APPSNCANFE2L2 | |
| SCHEMBL19183188 | 0.86 | MAOB (0.72) | AURKAABCG2MAOBMAOANFE2L2 | |
| SCHEMBL19183190 | 0.86 | MAOB (0.72) | AURKAABCG2MAOBMAOANFE2L2 | |
| SCHEMBL5084241 | 0.85 | AURKA (0.69) | AURKAABCG2APPMAOBMAOA | |
| SCHEMBL5084246 | 0.85 | AURKA (0.69) | AURKAABCG2APPMAOBMAOA | |
| SCHEMBL19183472 | 0.85 | AURKA (0.73) | AURKAABCG2MAOBMAOACYP3A4 | |
| SCHEMBL19183473 | 0.85 | AURKA (0.73) | AURKAABCG2MAOBMAOACYP3A4 | |
| SCHEMBL15619200 | 0.84 | MAOB (0.72) | AURKAABCG2MAOBMAOACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190008797-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-01-10 | — | — | US | disclosed |
| WO-2017132135-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190008797-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | ESRRG, GPER1, ESR2 | AURKA 4763/4885ABCG2 3643/4885APP 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.